Loading stock data…
Cerus Corporation operates as a biomedical products company (CERS)
$2.99+0.07 (+2.40%)
After Hours$2.96-0.03 (-1.00%)· Last close Jun 29
Cerus Corporation operates as a biomedical products company.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cerus Corporation in the Healthcare sector is trading at $2.99 with a market capitalization of $500M. Wall Street consensus targets $4.67 (3 analysts), implying a +56.1% move over the next 12 months. The stock is currently near its 52-week high of $3.15, remaining 45.9% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +56.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $53.66M↓ | $57.75M↑ | $52.70M↑ | $52.45M↑ | $43.24M |
| Gross Profit | $27.89M↓ | $29.75M↑ | $28.14M↓ | $28.98M↑ | $25.42M |
| Operating Income | -$354,000↑ | -$641,000↓ | $1.24M↑ | -$3.42M↑ | -$5.85M |
| Net Income | -$1.64M↑ | -$2.18M↓ | -$19,000↑ | -$5.71M↑ | -$7.72M |
Peer Comparison
JNJUNHPFE
Fundamentals
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$499.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-14.14%
Volume
Today's trading volume
2.31M
Recent News
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M
Cerus Corporation (NASDAQ:CERS) is one of the 8 Best Genomics Stocks to Buy According to Analysts. On June 8, Cerus Corporation (NASDAQ:CERS) closed a new debt facility with MidCap Financial, providing up to $110 million. The firm combined a five-year term loan with an asset-backed revolving loan. The company said the refinancing will cut annual […]
Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year?
Here is how BrightSpring Health Services, Inc. (BTSG) and Cerus (CERS) have performed compared to their sector so far this year.
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG
Cerus Corporation (NASDAQ:CERS) is one of the best oversold growth stocks to invest in now. BTIG upgraded Cerus Corporation (NASDAQ:CERS) to Buy from Neutral on May 1, reiterating a $4 price target. The rating update came after the company announced its financial results for fiscal Q1 2026, with total revenue for the quarter reaching $59.9 million, […]
3 Penny Stocks With Market Caps Under $500M And Promising Growth
Over the last 7 days, the United States market has dropped by 1.0%, but it remains up 23% over the past year, with earnings forecasted to grow by 17% annually. In such a dynamic landscape, identifying stocks that combine value and growth potential is key, especially when considering smaller or younger companies often referred to as penny stocks. Though the term may seem outdated, these investments can still offer significant opportunities for those looking to discover under-the-radar...
Cerebras IPO in focus as Nvidia earnings loom
Epistrophy Capital Research Chief Market Strategist and The Drill Down Podcast host Cory Johnson joins Market Catalysts to discuss the Cerebras IPO and key factors to watch in Nvidia’s (NVDA) upcoming earnings report.